All in FREE now.
Normally when FREE is down this much the next day the stock doubles...news looming finally.
This isn't a short play anymore...
Looks like a buy-out is coming any moment.
This stock is way too cheap now.
SNSS also missed it's primary endpoint and also decreased 90% in value the first week but rebounded 70% in just 3 days.
Instead of rebounding NYMX decreased another 50%.
Nymox had a marketcap of 170-200 million for years and today it's a lousy 17 million.
RSI is under14 and the stock is very very oversold.
I didn't see a SEC filing by insiders selling their shares also.
Almost the entire float of shares has been traded the last 8 days.
So what's going on here?
z @FiboZero · 10 nov.
Recordati $REC.mi Italians R Buying $NYMX EMA approval eminent
z @FiboZero · 3 hours ago
Recordati will b EMA approved for NX - 1207 BPH ...
FDA produced eroniuos placebo results... $NYMX
$ACAD $VVUS $OREX $ARIA $MNKD $ACHN $QQQ
Too late, it's almost worth zero...just 0.50 to go......but hey, it's already down 95% within 2 weeks...
DR.A, where are you?
I bet mister dr. A is selling his shares like crazy......he owns almost half of the company.....what a jerk.
AND THIS IS LEGAL?
and what about the huge bonusses management wants?
For what? For doing their job? Let management feel the risks of investing themselves instead of investor and bank's money.
There's no bottom yet.
This company is done.
No money. No drug.
No director that fight for his company.
I bet he's the one selling millions of his shares the last 7 days.
Next week we may see a SEC filing about insider selling.
If so, than Dr.A. has declared his company dead.
If you're right and the bottom is in today (0.55 is resistance) than we might see a nice bounce.
Previously reported study results showed that patients with NX-1207 treatment had significantly less Gleason grade progression, lower average PSA levels, lower numbers of biopsy cores showing greater malignancy, and lower total volume of more malignant cancer compared to controls.
To date, NX-1207 has had an excellent safety profile as both a treatment for benign prostatic hyperplasia (BPH) and localized low-risk prostate cancer. In the current trial, a new high dose of drug (15 mg) was safely used without drug-related adverse effects. NX-1207 has shown safety in repeat injection studies (NX02-0020 and NX02-0022). The drug does not lead to immune responses such as antibody formation which can cause significant drug toxicity and/or limit usage to single treatments due to drug neutralizing effects.
Paul Averback MD, CEO of Nymox said "These new results show the potential of NX-1207 to offer men with low-risk prostate cancer a significant tangible benefit in terms of avoidance of radiation and/or surgery and the related risks, discomforts, and permanent side effects. We emphasize that these results are based on a single injection only. A similar convenient treatment regimen with multiple injections is to be expected to offer even more benefit, which we hope to be able to demonstrate as soon as possible. If these positive results can be further validated, NX-1207 may prove to offer a new safe option for a painless way to deal with a major problem for many men."
Wow, what happened to you?
The positive thing is that yesterday a bullish doji star hes been formed.This pattern appears in a downtrend and warns that the trend will change.
Where're the lawsuits?